Novo Nordisk Inc v. Apotex Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Apotex Inc. (Canada)
  • Plaintiff's Counsel: Walsh Pizzi O'Reilly Falanga LLP
• Case Identification: 1:26-cv-01730, D.N.J., 02/20/2026
• Venue Allegations: Venue is asserted on the basis that Defendant is a foreign corporation not resident in the United States, and that the court has personal jurisdiction due to Defendant's business activities in New Jersey and prior consent to jurisdiction in the district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the diabetes drug RYBELSUS® constitutes an act of infringement of six patents covering the drug's composition and methods of use.
• Technical Context: The technology concerns oral formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of biologic drugs that historically required administration by injection.
• Key Procedural History: This action was commenced under the Hatch-Waxman Act within 45 days of Plaintiff receiving a Paragraph IV Certification Notice Letter from Defendant, dated January 30, 2026. The complaint notes that three of the patents-in-suit have been asserted against the same defendant in separate, pending litigation in the same district.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,278,123 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid"

• Patent Identification: U.S. Patent No. 9,278,123, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," issued March 8, 2016 Compl. ¶28

The Invention Explained

• Problem Addressed: The complaint does not specify the problem from the patent's background, but patents in this family describe the technical challenge of administering peptide drugs orally due to their degradation in the gastrointestinal tract and poor absorption U.S. Patent No. 10,278,923, col. 1:21-29
• The Patented Solution: The invention is a solid pharmaceutical composition designed for oral administration that combines the GLP-1 agonist semaglutide with an absorption enhancer, specifically a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, also known as SNAC Compl. ¶29 This combination is designed to protect the peptide and facilitate its absorption through the intestinal mucosa.
• Technical Importance: The technology represents a significant advancement in drug delivery by enabling oral administration of a complex biologic drug that was previously limited to parenteral (i.e., injection) routes.

Key Claims at a Glance

• The complaint asserts at least claim 9, which is a dependent claim Compl. ¶53 Compl. ¶58 The independent claim from which it depends is not identified.
• The complaint summarizes the scope of the patent as claiming, among other things, a solid composition comprising 5 to 20 mg of semaglutide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Compl. ¶29
• The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 10,278,923 - "Oral Dosing of GLP-1 Compounds"

• Patent Identification: U.S. Patent No. 10,278,923, "Oral Dosing of GLP-1 Compounds," issued May 7, 2019 Compl. ¶31

The Invention Explained

• Problem Addressed: The patent addresses the issue of high variability in patient plasma concentrations when administering oral GLP-1 peptides '923 Patent, col. 1:32-34 The specification notes that for long-acting peptides, a low-frequency oral dosing regimen (e.g., weekly) would have been expected, but this was found to result in unacceptable variability '923 Patent, col. 2:16-21 '923 Patent, col. 2:54-58
• The Patented Solution: The invention is based on the discovery that more frequent oral administration (e.g., daily) of a long half-life GLP-1 agonist surprisingly results in lower variability in plasma concentration '923 Patent, col. 2:46-54 The patent claims a method of treatment involving a specific dosing regimen where the ratio between the peptide's plasma half-life in days and the dosing interval in days is greater than 2:1 Compl. ¶32 '923 Patent, claim 14
• Technical Importance: This dosing strategy provides a method to achieve a more stable and predictable therapeutic effect from an orally administered long-acting peptide, which is critical for managing chronic diseases like diabetes.

Key Claims at a Glance

• The complaint asserts at least claim 14, which is an independent method claim Compl. ¶77
• Essential elements of independent claim 14 include:
  • A method for treating diabetes and/or obesity
  • comprising orally administering a solid oral dosage form composition
  • the composition comprises the GLP-1 peptide semaglutide (which has a plasma half-life of at least 60 hours) and an enhancer (SNAC)
  • the composition is administered such that the ratio of the plasma half-life (in days) to the dosing interval (in days) is more than 2:1
• The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 11,382,957 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid"

• Patent Identification: U.S. Patent No. 11,382,957, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," issued July 12, 2022 Compl. ¶34
• Technology Synopsis: The patent claims a solid composition for oral administration containing semaglutide (a GLP-1 agonist), a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC), and at least one excipient (lubricant, binder, or filler). A key feature is that the composition comprises at least 60% by weight of the SNAC salt Compl. ¶35
• Asserted Claims: At least claim 1 Compl. ¶99
• Accused Features: The specific formulation of Apotex's ANDA product, which is alleged to be identical or substantially identical to the composition of RYBELSUS® R2 Compl. ¶101

U.S. Patent No. 11,833,248 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid"

• Patent Identification: U.S. Patent No. 11,833,248, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," issued December 5, 2023 Compl. ¶37
• Technology Synopsis: The patent claims a pharmaceutical composition "consisting essentially of" semaglutide, magnesium stearate, and SNAC. The claims specify a ratio of 2-5 mg of magnesium stearate per 100 mg of SNAC and require that the composition does not comprise a binder or filler Compl. ¶38
• Asserted Claims: At least claim 1 Compl. ¶121
• Accused Features: The specific formulation of Apotex's ANDA product, alleged to be identical or substantially identical to RYBELSUS® R2 Compl. ¶123

U.S. Patent No. 12,396,953 - "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid"

• Patent Identification: U.S. Patent No. 12,396,953, "Solid Compositions Comprising a GLP-1 Agonist and a Salt of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid," issued August 26, 2025 Compl. ¶40
• Technology Synopsis: The patent claims a pharmaceutical composition comprising semaglutide, SNAC, and magnesium stearate. The claims recite specific amounts and ratios: semaglutide from 0.2 to 100 mg, magnesium stearate from 2-5 mg per 100 mg of SNAC, and SNAC constituting at least 95% by weight of the total excipients Compl. ¶41
• Asserted Claims: At least claim 1 Compl. ¶143
• Accused Features: The specific formulation of Apotex's ANDA product, alleged to be identical or substantially identical to RYBELSUS® R2 Compl. ¶145

U.S. Patent No. 12,514,822 - "Oral Dosing of GLP-1 Compounds"

• Patent Identification: U.S. Patent No. 12,514,822, "Oral Dosing of GLP-1 Compounds," issued January 6, 2026 Compl. ¶43
• Technology Synopsis: This patent claims a method for treating type 2 diabetes by orally administering a composition of semaglutide (0.5-50 mg) and SNAC. Similar to the '923 Patent, the method requires that the ratio between the plasma half-life of semaglutide (in days) and the dosing interval (in days) is more than 2:1 Compl. ¶44
• Asserted Claims: At least claim 1 Compl. ¶167
• Accused Features: The use of Apotex's ANDA product in accordance with its proposed label, which is expected to recommend a once-daily dosing schedule Compl. ¶169

III. The Accused Instrumentality

Product Identification

• Defendant Apotex's generic semaglutide tablets in 1.5 mg, 4 mg, and 9 mg dosage strengths, for which Apotex seeks FDA approval via ANDA No. 221238 ("Apotex's ANDA Product") Compl. ¶4 Compl. ¶14

Functionality and Market Context

• The accused product is a solid oral tablet intended to be a generic equivalent to Plaintiff's RYBELSUS® R2 product Compl. ¶4 The complaint alleges that the composition of Apotex's ANDA Product is "identical or substantially identical" to RYBELSUS® R2, containing the same active ingredient (semaglutide) and key inactive ingredients (SNAC and magnesium stearate) Compl. ¶51 Compl. ¶55
• The complaint alleges that Apotex's ANDA relies on Novo Nordisk's New Drug Application and contains data demonstrating the bioequivalence of its product to RYBELSUS® R2 Compl. ¶16 The product is intended for commercial sale throughout the United States upon FDA approval Compl. ¶15

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide the full text of the asserted claims for U.S. Patent No. 9,278,123. The infringement theory for this patent is summarized narratively. The complaint alleges that Plaintiff's RYBELSUS® R2 (9 mg) product is covered by at least claim 9 of the '123 Patent Compl. ¶53 It further alleges that Apotex's corresponding 9 mg generic tablet has a composition that is "identical or substantially identical" to RYBELSUS® R2 (9 mg) Compl. ¶55 Therefore, the filing of the ANDA for this product is alleged to be an act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶58

10,278,923 Infringement Allegations

• Identified Points of Contention:
  • Scope Questions (Composition Patents): For the family of composition patents ('123, '957, '248, '953), a central factual question will be whether the precise formulation of Apotex's product-including active ingredient amounts, excipients, weight percentages, and component ratios-meets every limitation of the asserted claims. For claims with negative limitations (e.g., '248 Patent, "does not comprise a binder or filler"), the presence of any such component in the accused product could be a point of dispute Compl. ¶38
  • Technical Questions (Method Patents): For the method patents ('923, '822), infringement is predicated on induced infringement. A key question will be whether Apotex's proposed label will be found to contain sufficient information and instruction for a user to recognize that they are practicing the claimed method, particularly the step requiring a specific ratio of drug half-life to dosing interval.

V. Key Claim Terms for Construction

For the patents analyzed in full, the following terms may be central to the dispute.

• Term: "plasma half-life in humans" ('923 Patent, Claim 14)
• Context and Importance: This term is a critical variable in the claimed ratio that defines the dosing method. The parties may dispute the proper methodology for determining this value and whether the value for semaglutide, as established in the art or on the product label, definitively meets the "at least 60 hours" limitation under the correct legal construction.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The term itself is a standard pharmacokinetic parameter. A party could argue it should be given its plain and ordinary meaning as understood by a person of ordinary skill in the art, encompassing any scientifically valid method of measurement.
  • Evidence for a Narrower Interpretation: The '923 patent specification includes a specific section titled "Method for Determining Plasma Half-Life" which describes plotting a plasma concentration-versus-time profile and performing a "non-compartmental pharmacokinetic analysis" '923 Patent, col. 6:32-52 A party could argue that this description limits the claim term to this specific methodology.

VI. Other Allegations

• Indirect Infringement: The complaint contains detailed allegations of induced infringement for the method patents ('923 and '822). It alleges that Apotex's ANDA "essentially copies" the RYBELSUS® Label and that by providing this label, Apotex "instructs, recommends, encourages, promotes, and/or suggests that physicians, prescribers, and/or patients" will administer the drug according to the claimed once-daily schedule, thereby directly infringing the method claims Compl. ¶79 Compl. ¶169 The complaint also alleges contributory infringement by stating that the accused product is "not a staple article of commerce and has no substantial approved uses that do not infringe" Compl. ¶81 Compl. ¶171
• Willful Infringement: The complaint does not use the term "willful infringement." However, it repeatedly alleges that Apotex's Detailed Statement, which sets forth its non-infringement and invalidity positions, is "devoid of an objective good faith basis in the facts or the law" and that the case is "exceptional" Compl. ¶65 Compl. ¶89 Compl. ¶111 Compl. ¶133 Compl. ¶155 Compl. ¶178 These allegations form the basis for a request for attorneys' fees under 35 U.S.C. § 285 and could potentially support a claim for enhanced damages. The complaint also alleges Apotex has "actual knowledge" of the patents Compl. ¶49 Compl. ¶71 Compl. ¶95 Compl. ¶117 Compl. ¶139 Compl. ¶161

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue for the composition-focused patents ('123, '957, '248, '953) will be one of compositional scope: will the exact formulation of Apotex's proposed generic product, including the precise amounts and weight-based percentages of semaglutide, SNAC, magnesium stearate, and any other excipients, fall within the boundaries of the various asserted claims, some of which contain narrow quantitative limitations and "consisting essentially of" language?
• A key legal and factual question for the method-of-use patents ('923, '822) will be induced infringement: does Apotex's proposed product label, by instructing a once-daily dosing regimen for a drug with a known long half-life, actively encourage or instruct a direct infringement of the claimed method, which is defined by a specific mathematical ratio of half-life to dosing interval?
• Given that this is an ANDA litigation arising from a Paragraph IV certification, a determinative question for the entire case will be patent validity: will Apotex be able to prove by clear and convincing evidence that the claims of the six asserted patents, which cover different aspects of the same commercial product, are invalid as obvious or anticipated in light of the prior art concerning oral delivery enhancers and GLP-1 agonist development?